Atorvastatin alleviates left ventricular remodeling in isoproterenol-induced chronic heart failure in rats by regulating the RhoA/Rho kinase signaling pathway.

Pharmacological Reports : PR
Dingjun SunZhongshu Liang

Abstract

Chronic heart failure (CHF) is characterized by left ventricular dysfunction and altered autonomic control of cardiac function. This study aimed to investigate the effects of atorvastatin on left ventricular remodeling (LVR) and cardiac function in rats with isoproterenol-induced CHF and the possible mechanism. An isoproterenol-induced CHF model was established in rata, which were subsequently treated with atorvastatin. Echocardiography, hemodynamic, and left ventricular mass indexes were assessed. The mRNA expression of RhoA, Rho kinase, and endothelial nitric oxide synthase (eNOS) was determined by RT-qPCR. The protein expression of myosin-binding subunit (MBS), MBS-P, eNOS, phosphorylated-eNOS, RhoA, and Rho kinase was measured by Western blot analysis. The relative activity of NADPH oxidase, ROS, and NO was assessed by ELISA. Isoproterenol-induced CHF rats treated with atorvastatin exhibited decreased left ventricular end-systolic dimension, left ventricular end-diastolic dimension, left ventricular end-diastolic pressure, left ventricular mass index, maximum fall rate of change in left ventricular pressure, heart rate (p < 0.001), expression of RhoA, Rho kinase, MBS and MBS-P (p < 0.01), and relative activity of NADPH oxid...Continue Reading

References

Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Jul 19, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Kathryn BatesMohamed A Gaballa
Apr 26, 2003·American Journal of Respiratory Cell and Molecular Biology·Zhiqian WangRodney A Rhoades
Nov 14, 2003·Cardiovascular Research·Jean-Noel TrochuThomas H Hintze
Apr 20, 2005·International Journal of Cardiology·Dimitris TousoulisChristodoulos Stefanadis
Dec 19, 2006·International Journal of Cardiology·Dimitris TousoulisChristodoulos Stefanadis
Jun 29, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jonel TrebickaJörg Heller
May 2, 2009·European Journal of Heart Failure·Michael ShechterDov Freimark
Jul 17, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Paul M Vanhoutte
Jul 9, 2010·Journal of Cardiac Failure·UNKNOWN Heart Failure Society of AmericaMary N Walsh
Jul 17, 2010·Annals of the New York Academy of Sciences·W Gibson WoodWalter E Müller
Sep 14, 2010·Pulmonary Pharmacology & Therapeutics·Michelle J Connolly, Philip I Aaronson
Dec 17, 2010·Circulation·Véronique L RogerUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
May 31, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Ryan P MorrisseyPrediman K Shah
Sep 21, 2011·Future Cardiology·Michelle SurmaJianjian Shi
Oct 5, 2011·Journal of Molecular and Cellular Cardiology·Pitchai BalakumarNanjaian Mahadevan
Oct 18, 2011·Pharmacological Reports : PR·Magdalena Jasińska-StroscheinDaria Orszulak-Michalak
Jun 9, 2012·European Journal of Heart Failure·Eduard ShantsilaGregory Y H Lip
Oct 11, 2013·Clinical and Experimental Pharmacology & Physiology·Hao LiYou-Yi Zhang
Feb 4, 2016·Circulation Research·Hiroaki ShimokawaKimio Satoh
Apr 8, 2017·Oncotarget·Jiuchun QiuGuangping Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.